… Colchicine should not be given to patients receiving strong P-glycoprotein and/or CYP3A4 …
A pharmacokinetic study73 showed that strong P-glycoprotein and/or CYP3A4 inhibitors such …

Objectives To agree terminology and to develop recommendations for the diagnosis of calcium
pyrophosphate deposition (CPPD). Methods The European League Against Rheumatism …

Asymptomatic MSU crystals deposits can now be identified and precede the onset of gout
flares. Defining hyperuricemia as greater than 6 mg/dl would have the advantage to give the …

In contrast to the accepted general assumption that polyethylene glycol (PEG) is non-immunogenic
and non-antigenic, animal studies clearly showed that uricase, ovalbumin and some …

Background Given the phenotypic similarities between rheumatoid arthritis (RA)–associated
interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we …

… analyses was superior with celecoxib than with the combination (p<0.001 for the imputed
per-protocol population and p=0.002 for the imputed intention-to-treat sensitivity population). …

… in insulin levels (p=0.02) and insulin resistance (p=0.05). … hsCRP (r=0.42; p=0.006) and
Helix-II (r=0.37; p=0.01). Levels … (r=0.63; p<0.0001) and orosomucoid (r=0.33; p=0.03). None of …

The prevalence of osteoarthritis (OA) and the burden associated with the disease are
steadily increasing worldwide, representing a major public health challenge for the coming …

Abbreviations used in this article: ATS, American Thoracic Society; CDC, Centers for Disease
Control and Prevention; CT, computed tomography; HIV, human immunodeficiency virus; …

Objectives To develop evidence-based recommendations for management of calcium
pyrophosphate deposition (CPPD). Methods A multidisciplinary guideline development group of …